Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody (vol 113, pg 1062, 2009)

被引：0
|
作者：
Goldenberg
机构：
来源：
BLOOD | 2009年 / 113卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：5368 / 5368
页数：1
相关论文
共 50 条
  • [31] Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation (vol 265, pg 1115, 2018)
    Tallantyre, E. C.
    Whittam, D. H.
    Jolles, S.
    Paling, D.
    Constantinescu, C.
    Robertson, N. P.
    Jacob, A.
    JOURNAL OF NEUROLOGY, 2018, 265 (05) : 1123 - 1123
  • [32] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Shi, V
    Hayes, M
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878
  • [33] Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb
    Goldenberg, David M.
    Govindan, Serengulam
    Cardillo, Tom M.
    Sharkey, Robert M.
    BLOOD, 2010, 116 (21) : 1607 - 1607
  • [34] Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis
    Tacke, Sabine
    Chunder, Rittika
    Schropp, Verena
    Urich, Eduard
    Kuerten, Stefanie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [35] BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties
    Nishida, Michio
    Uematsu, Norio
    Kobayashi, Hideaki
    Matsunaga, Yuka
    Ishida, Shoko
    Takata, Minoru
    Niwa, Ohtsura
    Padlan, Eduardo A.
    Newman, Roland
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (02) : 335 - 344
  • [36] Peripheral T-cell lymphoma after anti-CD20 antibody therapy - In reply (vol 16, pg 1636, 1998)
    Maloney, DG
    Davis, T
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 2001 - 2001
  • [37] Successful living related donor kidney transplantation after treatment of post transplant lymphoproliferative disorder (PTLD) using humanized anti-CD20 monoclonal antibody (Rituximab).
    Al Saghier, MI
    Abdo, AA
    Al Hassoun, IA
    Hamawi, K
    Al Sofayan, MS
    Al Akash, SI
    Al Abbad, AA
    Al Shaibani, KM
    Al Meshari, KAM
    Al Sebayel, MI
    Khalaf, HA
    Al Ahmadi, IS
    Chaballout, A
    Al Bahili, HM
    El-Sheikh, YM
    LIVER TRANSPLANTATION, 2006, 12 (05) : C5 - C5
  • [38] AME-133v, a humanized, Fc-engineered anti-CD20 monoclonal antibody, demonstrates greater B cell depletion than Rituxan in vitro
    Wayne, Jennifer L.
    Campbell, Mary-Ann
    Marulappa, Shashi
    Jain, Vinay
    CANCER RESEARCH, 2012, 72
  • [39] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [40] Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
    Genovese, Mark C.
    Kaine, Jeffrey L.
    Lowenstein, Mitchell B.
    Del Giudice, Jose
    Baldassare, Andrew
    Schechtman, Joy
    Fudman, Edward
    Kohen, Michael
    Gujrathi, Shelia
    Trapp, Robert G.
    Sweiss, Nadera J.
    Spaniolo, Greg
    Dummer, Wolfgang
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : 2652 - 2661
12345